IMDELLTRA® Plus IMFINZI® Shows Landmark Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer Amgen (NASDAQ: AMGN) announced landmark results from the Phase 3 DeLLphi-305 study, reporting that the trial met its primary endpoint at a pre-specified interim analysis…
Johnson & Johnson to Present 24 Neuropsychiatry Data Sets at Psych Congress 2026 Johnson & Johnson (NYSE: JNJ) will present 24 abstracts featuring clinical trial data and real-world evidence from across its neuropsychiatry portfolio at the 2026 Psych Congress Annual…
Strata Mental Health Solutions Awarded Compass Pathways Grant to Develop U.S. Provider Training for COMP360 Strata Mental Health Solutions, an expert-led training and implementation partner focused on preparing clinical networks to deliver regulated psychedelic treatments, has been selected as one…
Bausch + Lomb Receives European CE Mark for Next-Generation SeeLyra Femtosecond Laser Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company focused on helping people see better and live better, has announced that its next-generation SeeLyra femtosecond laser…
Johnson & Johnson Receives CE Mark for ACUVUE OASYS MAX 2-Week Reusable Contact Lens Johnson & Johnson (NYSE: JNJ) announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens designed to provide enhanced…
IMDS Launches NHanceIT Microcatheter in the U.S. for Complex Coronary Interventions Interventional Medical Device Solutions (IMDS), a specialty catheter company developing purpose-built technologies for complex percutaneous coronary intervention (PCI), chronic total occlusion (CTO), and complex high-risk indicated procedures (CHIP), has…
PureTech Health Notes Positive Phase 1 Driving Trial Results for GlyphAllo in Major Depressive Disorder PureTech Health plc (LSE: PRTC), a biotherapeutics company operating through a hub-and-spoke model to translate scientific innovation into potentially transformative medicines, has highlighted positive topline…
Gossamer Bio Announces 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary vascular diseases, has announced that its Board of Directors has selected a…
Nanochon Treats First Patient in First-in-Human Clinical Study of Chondrograft for Knee Cartilage Defects Nanochon, a medical device company developing innovative solutions for cartilage repair, has announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study…
Sarepta Therapeutics Announces 25 Recipients of Route 79 Duchenne Scholarship Program for 2026-2027 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a company focused on precision genetic medicine for rare diseases, has announced the 25 recipients of its Route 79, The Duchenne Scholarship…
Lineage Cell Therapeutics Receives U.S. Patent Covering AlloSCOPE 5D Cell Manufacturing Platform Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing novel allogeneic, “off-the-shelf” cell therapies for serious medical conditions, has announced an…
RiboX Therapeutics Receives FDA RMAT Designation for RXRG001 in Radiation-Induced Xerostomia RiboX Therapeutics, a clinical-stage biotechnology company focused on discovering and developing fully engineered circular RNA (circRNA) therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative…